CATX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
20.0K
-75.3%
81.0K
+6.6%
76.0K
+76.7%
43.0K
-79.4%
209.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
20.0K
-75.3%
81.0K
+6.6%
76.0K
+76.7%
43.0K
-79.4%
209.0K
Operating Expenses
34.3M
+17.1%
29.3M
+3.5%
28.4M
-28.9%
39.9M
+42.1%
28.1M
R&D
26.1M
+21.0%
21.5M
+0.8%
21.4M
-35.1%
32.9M
+61.9%
20.3M
SG&A
8.3M
+6.1%
7.8M
+11.6%
7.0M
+0.5%
7.0M
-10.1%
7.7M
Operating Income
-34322000
-17.3%
-29258000
-3.5%
-28281000
+29.0%
-39832000
-43.0%
-27861000
EBITDA
-33129000
-17.8%
-28117000
-3.5%
-27155000
+30.1%
-38821000
-43.3%
-27086000
Net Income
-32442000
-21.1%
-26786000
-2.3%
-26189000
+30.1%
-37490000
-44.4%
-25969000
EPS (Basic)
$-0.27
-22.7%
$-0.22
+12.0%
$-0.25
+50.0%
$-0.50
-42.9%
$-0.35
EPS (Diluted)
$-0.27
-22.7%
$-0.22
+12.0%
$-0.25
+50.0%
$-0.50
-42.9%
$-0.35
Shares (Diluted)
120.7M
+0.1%
120.7M
+16.5%
103.6M
+39.3%
74.4M
+0.1%
74.3M
Perspective Therapeutics (CATX) — Financials